AbbVie (ABBV) News Today $228.57 -2.82 (-1.22%) Closing price 03:59 PM EasternExtended Trading$229.38 +0.81 (+0.35%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is AbbVie Down Today?Toggle Visibility of Why Is AbbVie Down Today?AbbVie Inc. (ABBV) — shares are down after a mixed news flow. Positive catalysts (strong drug wins, pipeline progress and M&A) support upside, but near-term selling and analyst EPS cuts are weighing on the stock following a large run-up earlier this year. Positive Sentiment: Key trial result: AbbVie's Rinvoq outperformed Humira in a major arthritis trial — a clinical win that supports continued commercial momentum for its immunology franchise. Article Title Positive Sentiment: Migraine pipeline progress: Positive Phase 3 update for atogepant signals growth beyond core immunology drugs and strengthens long-term revenue diversification. Article Title Positive Sentiment: M&A: AbbVie completed the acquisition of Gilgamesh Pharma (bretilsilocin), expanding its CNS/migraine portfolio and pipeline breadth. Article Title Positive Sentiment: Analyst support: A Cerity Partners commentator highlighted AbbVie’s attractive valuation and dividend yield, which can attract income-focused buyers. Article Title Neutral Sentiment: Momentum note: Zacks and other outlets highlight that ABBV is up >30% in six months driven by Skyrizi/Rinvoq and oncology gains — that explains some recent profit-taking. Article Title Neutral Sentiment: Investor interest: Zacks and MarketBeat pieces note ABBV as a trending/long-term dividend pick, underscoring buy-and-hold narratives even as volatility continues. Article Title Negative Sentiment: Estimate cuts: Zacks Research trimmed Q1 2026 EPS forecasts and flagged a negative near-term outlook, which likely contributed to downward pressure on the share price. Article Title Takeaway for investors: the stock’s pullback reflects short-term profit-taking and an analyst EPS reduction despite tangible product- and pipeline-driven positives (Rinvoq/Skyrizi momentum, migraine program, M&A). If you hold ABBV, weigh near-term estimate risk against durable cash flow, dividend strength and recent clinical/commercial catalysts.Posted 16m agoAI Generated. May Contain Errors. ABBV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation1 hour ago | insidermonkey.comEthic Inc. Lowers Holdings in AbbVie Inc. $ABBVOctober 22 at 9:39 AM | marketbeat.comCaliber Wealth Management LLC KS Purchases 12,608 Shares of AbbVie Inc. $ABBVOctober 22 at 9:27 AM | marketbeat.comZacks Research Issues Negative Outlook for AbbVie EarningsOctober 22 at 7:57 AM | marketbeat.comAbbVie Inc. $ABBV Shares Purchased by Family Capital Management Inc.October 22 at 7:56 AM | marketbeat.comExencial Wealth Advisors LLC Cuts Position in AbbVie Inc. $ABBVOctober 22 at 7:42 AM | marketbeat.comBrookstone Capital Management Sells 2,453 Shares of AbbVie Inc. $ABBVOctober 22 at 7:28 AM | marketbeat.comD.A. Davidson & CO. Reduces Stake in AbbVie Inc. $ABBVOctober 22 at 6:57 AM | marketbeat.comGables Capital Management Inc. Has $650,000 Position in AbbVie Inc. $ABBVOctober 22 at 6:49 AM | marketbeat.comCullen Frost Bankers Inc. Acquires 11,730 Shares of AbbVie Inc. $ABBVOctober 22 at 6:48 AM | marketbeat.comAbbVie's Rinvoq Beats Humira in Key Arthritis TrialOctober 21 at 1:29 PM | finance.yahoo.comAbbVie’s Atogepant Study: A Step Forward in Migraine PreventionOctober 21 at 12:31 PM | tipranks.comThe Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant RecipientsOctober 21 at 8:00 AM | prnewswire.comAbbVie Inc. $ABBV Shares Sold by Sanders Morris Harris LLCOctober 21 at 7:14 AM | marketbeat.comAbbVie Inc. $ABBV Shares Sold by Beech Hill Advisors Inc.October 21 at 7:13 AM | marketbeat.comDupont Capital Management Corp Decreases Position in AbbVie Inc. $ABBVOctober 21 at 6:51 AM | marketbeat.comWhittier Trust Co. Buys 9,073 Shares of AbbVie Inc. $ABBVOctober 21 at 6:32 AM | marketbeat.comDivergent Planning LLC Purchases Shares of 4,006 AbbVie Inc. $ABBVOctober 21 at 6:24 AM | marketbeat.comTriton Financial Group Inc Makes New Investment in AbbVie Inc. $ABBVOctober 21 at 5:55 AM | marketbeat.comAbbVie Inc. $ABBV Shares Acquired by VCI Wealth Management LLCOctober 21 at 5:55 AM | marketbeat.comAbbVie Inc. $ABBV Stock Holdings Decreased by Clune & Associates LTD.October 21 at 5:54 AM | marketbeat.comKlingman & Associates LLC Purchases 1,371 Shares of AbbVie Inc. $ABBVOctober 21 at 5:46 AM | marketbeat.comSecurian Asset Management Inc. Decreases Stock Holdings in AbbVie Inc. $ABBVOctober 21 at 5:45 AM | marketbeat.comPhoenix Financial Ltd. Purchases 2,152 Shares of AbbVie Inc. $ABBVOctober 21 at 5:37 AM | marketbeat.comAbbVie (NYSE:ABBV) Trading Up 1.1% - Here's What HappenedOctober 20 at 8:19 PM | marketbeat.comAbbVie's Rinvoq shows superiority over Humira in head-to-head studyOctober 20 at 8:12 AM | reuters.comDekaBank Deutsche Girozentrale Has $560.87 Million Position in AbbVie Inc. $ABBVOctober 20 at 6:17 AM | marketbeat.comTownsend & Associates Inc Buys Shares of 11,695 AbbVie Inc. $ABBVOctober 20 at 5:24 AM | marketbeat.comCMG Global Holdings LLC Has $392,000 Stake in AbbVie Inc. $ABBVOctober 20 at 5:24 AM | marketbeat.comBalboa Wealth Partners Acquires 1,325 Shares of AbbVie Inc. $ABBVOctober 20 at 5:24 AM | marketbeat.comAbbVie Inc. $ABBV Shares Sold by Birmingham Capital Management Co. Inc. ALOctober 20 at 5:24 AM | marketbeat.comAbbVie price target raised to $250 from $236 at Raymond JamesOctober 19 at 7:46 PM | msn.comChicago Partners Investment Group LLC Increases Stock Holdings in AbbVie Inc. $ABBVOctober 19 at 6:39 AM | marketbeat.comAull & Monroe Investment Management Corp Has $2.79 Million Holdings in AbbVie Inc. $ABBVOctober 19 at 6:31 AM | marketbeat.comWendell David Associates Inc. Sells 2,106 Shares of AbbVie Inc. $ABBVOctober 19 at 6:22 AM | marketbeat.comViolich Capital Management Inc. Sells 12,770 Shares of AbbVie Inc. $ABBVOctober 19 at 6:06 AM | marketbeat.comAbbVie Inc. $ABBV Shares Sold by Goldstein Advisors LLCOctober 19 at 5:56 AM | marketbeat.comVIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Stake in AbbVie Inc. $ABBVOctober 19 at 5:37 AM | marketbeat.comAbbVie Inc. $ABBV Position Lifted by TrueMark Investments LLCOctober 19 at 5:30 AM | marketbeat.comMutual of America Capital Management LLC Sells 3,730 Shares of AbbVie Inc. $ABBVOctober 19 at 5:21 AM | marketbeat.comFY2025 EPS Estimates for AbbVie Lifted by Cantor FitzgeraldOctober 19 at 2:41 AM | americanbankingnews.comAbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocinOctober 18, 2025 | finance.yahoo.comNovare Capital Management LLC Buys 1,362 Shares of AbbVie Inc. $ABBVOctober 18, 2025 | marketbeat.comAbbVie Inc. $ABBV Holdings Lifted by Hamlin Capital Management LLCOctober 18, 2025 | marketbeat.comCurbstone Financial Management Corp Reduces Holdings in AbbVie Inc. $ABBVOctober 18, 2025 | marketbeat.comHuntleigh Advisors Inc. Grows Stock Position in AbbVie Inc. $ABBVOctober 18, 2025 | marketbeat.comAbbVie Inc. $ABBV Position Increased by Hartline Investment CorpOctober 18, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of AbbVie Q3 EarningsOctober 18, 2025 | americanbankingnews.comAbbVie executive Greg Miley to lead corporate affairs at Novo Nordisk - ReutersOctober 17, 2025 | za.investing.comNovo taps U.S. pharma veteran from AbbVie amid drug pricing scrutinyOctober 17, 2025 | msn.com Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Media Mentions By Week ABBV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABBV News Sentiment▼1.030.50▲Average Medical News Sentiment ABBV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABBV Articles This Week▼8351▲ABBV Articles Average Week Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AMGN News Today GILD News Today MRNA News Today ABT News Today BMY News Today JNJ News Today LLY News Today MRK News Today PFE News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ABBV) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.